While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.
While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.
Transcript
What has been your experience with commercial payer contracts on the use of biosimilars? Are they encouraging biosimilar use?
In our experience, commercial payers are wanting to move to biosimilars. Many of them—because of what they do and having to be held accountable to their employers and other people who are buying services from the insurers—they do want to utilize services that lower the cost of care. We have seen a shift to biosimilars for our commercial payers.
I’ll say the challenge with them is that each one of them want to pick a winner that they like, which makes it extremely challenging for a practice to have to shift gears for every patient that walks in the door and use the insurer’s “preferred biosimilar” versvsus just using biosimilars. And we always advocate for physician choice and that if we're going to use biosimilars, let us be able to pick the biosimilar that we want to use so it's much easier on a practice to be able to manage their patient population, rather than having to switch gears with every single patient that walks in the door.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More